[Ip-health] Federal Register :: The Future of Insulin Biosimilars: Increasing Access and Facilitating the Efficient Development of Biosimilar and Interchangeable Insulin Products; Public Hearing; Request for Comments

James Love james.love at keionline.org
Thu Apr 4 05:19:32 PDT 2019



The Food and Drug Administration (FDA or the Agency) is announcing a public
hearing to discuss access to affordable insulin products and issues related
to the development and approval of biosimilar and interchangeable insulin


The public hearing will be held on May 13, 2019, from 9 a.m. to 5 p.m. The
public hearing may be extended or may end early depending on the level of
public participation. Persons seeking to present at the public hearing must
register by April 29, 2019. Persons seeking to speak at the public hearing
must register by May 9, 2019. Persons seeking to attend, but not present
at, the public hearing must register by May 9, 2019. Section III provides
attendance and registration information. Electronic or written comments
will be accepted after the public hearing until May 31, 2019.

. . .

More information about the Ip-health mailing list